1. Home
  2. PASG vs ZDAI Comparison

PASG vs ZDAI Comparison

Compare PASG & ZDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PASG
  • ZDAI
  • Stock Information
  • Founded
  • PASG 2017
  • ZDAI 2022
  • Country
  • PASG United States
  • ZDAI Hong Kong
  • Employees
  • PASG N/A
  • ZDAI N/A
  • Industry
  • PASG Biotechnology: Pharmaceutical Preparations
  • ZDAI General Bldg Contractors - Nonresidential Bldgs
  • Sector
  • PASG Health Care
  • ZDAI Consumer Discretionary
  • Exchange
  • PASG Nasdaq
  • ZDAI Nasdaq
  • Market Cap
  • PASG 20.3M
  • ZDAI 20.6M
  • IPO Year
  • PASG 2020
  • ZDAI 2024
  • Fundamental
  • Price
  • PASG $7.44
  • ZDAI $0.60
  • Analyst Decision
  • PASG Strong Buy
  • ZDAI
  • Analyst Count
  • PASG 3
  • ZDAI 0
  • Target Price
  • PASG $153.33
  • ZDAI N/A
  • AVG Volume (30 Days)
  • PASG 98.1K
  • ZDAI 60.7K
  • Earning Date
  • PASG 08-07-2025
  • ZDAI 08-15-2025
  • Dividend Yield
  • PASG N/A
  • ZDAI N/A
  • EPS Growth
  • PASG N/A
  • ZDAI N/A
  • EPS
  • PASG N/A
  • ZDAI N/A
  • Revenue
  • PASG N/A
  • ZDAI $17,166,534.00
  • Revenue This Year
  • PASG N/A
  • ZDAI N/A
  • Revenue Next Year
  • PASG N/A
  • ZDAI N/A
  • P/E Ratio
  • PASG N/A
  • ZDAI $19.05
  • Revenue Growth
  • PASG N/A
  • ZDAI 56.11
  • 52 Week Low
  • PASG $5.12
  • ZDAI $0.37
  • 52 Week High
  • PASG $26.60
  • ZDAI $107.36
  • Technical
  • Relative Strength Index (RSI)
  • PASG 53.78
  • ZDAI N/A
  • Support Level
  • PASG $5.12
  • ZDAI N/A
  • Resistance Level
  • PASG $5.99
  • ZDAI N/A
  • Average True Range (ATR)
  • PASG 0.88
  • ZDAI 0.00
  • MACD
  • PASG -0.03
  • ZDAI 0.00
  • Stochastic Oscillator
  • PASG 58.25
  • ZDAI 0.00

About PASG Passage Bio Inc.

Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.

Share on Social Networks: